For more than 20 years, AbbVie has been dedicated to improving care for people living with immune disorders. Our longstanding commitment is underscored by our pursuit of cutting-edge science to improve our understanding of complex inflammatory disorders and to ultimately help patients better manage their disease.
By innovating, learning and adapting, AbbVie aspires to reduce the burden of IBD and make a positive long-term impact on people’s lives.
For more information, visit https://www.abbvie.co.uk/
UK-ABBV-210920
November 2021